| Bioactivity | Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury[1][2][3]. |
| CAS | 216167-95-2 |
| Formula | C35H54O4S2 |
| Molar Mass | 602.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dussault S, et al. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation[J]. Atherosclerosis, 2014, 237(1): 194-199. [2]. Murata S, et al. Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis[J]. Transplantation, 2004, 77(10): 1494-1500. [3]. First M R, et al. New drugs to improve transplant outcomes[J]. Transplantation, 2004, 77(9): S88-S92. |
Elsibucol
CAS: 216167-95-2 F: C35H54O4S2 W: 602.93
Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.